0 CHECKOUT

Diabetic Macular Edema - Pipeline Review, H2 2015

  • ID: 3500414
  • October 2015
  • 199 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Aciont Inc.
  • Allergan Plc
  • EyeGene, Inc.
  • Icon Bioscience, Inc.
  • MacuCLEAR, Inc.
  • Ohr Pharmaceutical Inc.
  • MORE

Diabetic Macular Edema - Pipeline Review, H2 2015

Summary

The report ‘Diabetic Macular Edema - Pipeline Review, H2 2015’, provides an overview of the Diabetic Macular Edema’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Diabetic Macular Edema, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Macular Edema and special features on late-stage and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updates following a stringent READ MORE >

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Aciont Inc.
  • Allergan Plc
  • EyeGene, Inc.
  • Icon Bioscience, Inc.
  • MacuCLEAR, Inc.
  • Ohr Pharmaceutical Inc.
  • MORE

List of Tables

List of Figures

Introduction

REPORT COVERAGE

Diabetic Macular Edema Overview

Therapeutics Development

Pipeline Products for Diabetic Macular Edema - Overview

Pipeline Products for Diabetic Macular Edema - Comparative Analysis

Diabetic Macular Edema - Therapeutics under Development by Companies

Diabetic Macular Edema - Therapeutics under Investigation by Universities/Institutes

Diabetic Macular Edema - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Unknown Stage Products

Diabetic Macular Edema - Products under Development by Companies

Diabetic Macular Edema - Products under Investigation by Universities/Institutes

Diabetic Macular Edema - Companies Involved in Therapeutics Development

Aciont Inc.

ActiveSite Pharmaceuticals, Inc.

Acucela Inc.

Aerpio Therapeutics, Inc.

Allergan Plc

Ampio Pharmaceuticals, Inc.

Astellas Pharma Inc.

Avalanche Biotechnologies, Inc.

Chengdu Kanghong Pharmaceuticals Group Co., Ltd.

Chong Kun Dang Pharmaceutical Corp.

Dyax Corp.

EyeGate Pharmaceuticals, Inc.

EyeGene, Inc.

F. Hoffmann-La Roche Ltd.

Gene Signal International SA

Genmab A/S

Icon Bioscience, Inc.

Kala Pharmaceuticals, Inc.

Kowa Company, Ltd.

Mabion SA

MacuCLEAR, Inc.

NicOx S.A.

Oculis ehf

Ohr Pharmaceutical Inc.

Pfizer Inc.

Quark Pharmaceuticals, Inc.

R-Tech Ueno, Ltd.

Regeneron Pharmaceuticals, Inc.

Santen Pharmaceutical Co., Ltd.

SciFluor Life Sciences, LLC

Senju Pharmaceutical Co., Ltd.

ThromboGenics NV

Verseon Corporation

Diabetic Macular Edema - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Combination Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

(aflibercept + nesvacumab) - Drug Profile

abicipar pegol - Drug Profile

aganirsen - Drug Profile

AKB-9778 - Drug Profile

ALG-1001 - Drug Profile

Antibodies to Inhibit Hemopexin for Diabetic Macular Edema - Drug Profile

ASP-440 - Drug Profile

ASP-8232 - Drug Profile

AVA-101 - Drug Profile

conbercept - Drug Profile

danazol - Drug Profile

dexamethasone acetate - Drug Profile

dexamethasone acetate - Drug Profile

dexamethasone dipropionate - Drug Profile

difluprednate - Drug Profile

Drug for Diabetic Macular Edema - Drug Profile

Drugs to Inhibit Semaphorin 3A for Diabetic Macular Edema - Drug Profile

Drugs to Inhibit Tyrosine Kinase for Ophthalmology - Drug Profile

EG-Mirotin - Drug Profile

emixustat hydrochloride - Drug Profile

KVD-001 - Drug Profile

lanadelumab - Drug Profile

LKA-651 - Drug Profile

loteprednol etabonate - Drug Profile

MC-4001 - Drug Profile

methotrexate - Drug Profile

MTP-131 - Drug Profile

NCX-422 - Drug Profile

NCX-434 - Drug Profile

nesvacumab - Drug Profile

NM-108 - Drug Profile

ocriplasmin (recombinant) - Drug Profile

OLX-303 - Drug Profile

PF-04634817 - Drug Profile

PF-655 - Drug Profile

ranibizumab - Drug Profile

ranibizumab biosimilar - Drug Profile

ranibizumab biosimilar - Drug Profile

RC-1 Alpha - Drug Profile

ripasudil - Drug Profile

RTU-1096 - Drug Profile

RX-10045 - Drug Profile

SF-0166 - Drug Profile

Small Molecule for Diabetic Macular Edema - Drug Profile

Small Molecule to Inhibit Kallikrein for DME - Drug Profile

Small Molecules to Inhibit Plasma Kallikrein for DME and HAE - Drug Profile

Small Molecules to Inhibit VAP-1 for Diabetic Macular Edema - Drug Profile

squalamine lactate - Drug Profile

teprotumumab - Drug Profile

TG-758 - Drug Profile

TG-931 - Drug Profile

triamcinolone acetonide - Drug Profile

Diabetic Macular Edema - Recent Pipeline Updates

Diabetic Macular Edema - Dormant Projects

Diabetic Macular Edema - Discontinued Products

Diabetic Macular Edema - Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Diabetic Macular Edema, H2 2015

Number of Products under Development for Diabetic Macular Edema - Comparative Analysis, H2 2015

Number of Products under Development by Companies, H2 2015

Number of Products under Investigation by Universities/Institutes, H2 2015

Comparative Analysis by Late Stage Development, H2 2015

Comparative Analysis by Clinical Stage Development, H2 2015

Comparative Analysis by Early Stage Development, H2 2015

Comparative Analysis by Unknown Stage Development, H2 2015

Products under Development by Companies, H2 2015

Products under Development by Companies, H2 2015 (Contd..1)

Products under Development by Companies, H2 2015 (Contd..2)

Products under Investigation by Universities/Institutes, H2 2015

Diabetic Macular Edema - Pipeline by Aciont Inc., H2 2015

Diabetic Macular Edema - Pipeline by ActiveSite Pharmaceuticals, Inc., H2 2015

Diabetic Macular Edema - Pipeline by Acucela Inc., H2 2015

Diabetic Macular Edema - Pipeline by Aerpio Therapeutics, Inc., H2 2015

Diabetic Macular Edema - Pipeline by Allergan Plc, H2 2015

Diabetic Macular Edema - Pipeline by Ampio Pharmaceuticals, Inc., H2 2015

Diabetic Macular Edema - Pipeline by Astellas Pharma Inc., H2 2015

Diabetic Macular Edema - Pipeline by Avalanche Biotechnologies, Inc., H2 2015

Diabetic Macular Edema - Pipeline by Chengdu Kanghong Pharmaceuticals Group Co., Ltd., H2 2015

Diabetic Macular Edema - Pipeline by Chong Kun Dang Pharmaceutical Corp., H2 2015

Diabetic Macular Edema - Pipeline by Dyax Corp., H2 2015

Diabetic Macular Edema - Pipeline by EyeGate Pharmaceuticals, Inc., H2 2015

Diabetic Macular Edema - Pipeline by EyeGene, Inc., H2 2015

Diabetic Macular Edema - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015

Diabetic Macular Edema - Pipeline by Gene Signal International SA, H2 2015

Diabetic Macular Edema - Pipeline by Genmab A/S, H2 2015

Diabetic Macular Edema - Pipeline by Icon Bioscience, Inc., H2 2015

Diabetic Macular Edema - Pipeline by Kala Pharmaceuticals, Inc., H2 2015

Diabetic Macular Edema - Pipeline by Kowa Company, Ltd., H2 2015

Diabetic Macular Edema - Pipeline by Mabion SA, H2 2015

Diabetic Macular Edema - Pipeline by MacuCLEAR, Inc., H2 2015

Diabetic Macular Edema - Pipeline by NicOx S.A., H2 2015

Diabetic Macular Edema - Pipeline by Oculis ehf, H2 2015

Diabetic Macular Edema - Pipeline by Ohr Pharmaceutical Inc., H2 2015

Diabetic Macular Edema - Pipeline by Pfizer Inc., H2 2015

Diabetic Macular Edema - Pipeline by Quark Pharmaceuticals, Inc., H2 2015

Diabetic Macular Edema - Pipeline by R-Tech Ueno, Ltd., H2 2015

Diabetic Macular Edema - Pipeline by Regeneron Pharmaceuticals, Inc., H2 2015

Diabetic Macular Edema - Pipeline by Santen Pharmaceutical Co., Ltd., H2 2015

Diabetic Macular Edema - Pipeline by SciFluor Life Sciences, LLC, H2 2015

Diabetic Macular Edema - Pipeline by Senju Pharmaceutical Co., Ltd., H2 2015

Diabetic Macular Edema - Pipeline by ThromboGenics NV, H2 2015

Diabetic Macular Edema - Pipeline by Verseon Corporation, H2 2015

Assessment by Monotherapy Products, H2 2015

Assessment by Combination Products, H2 2015

Number of Products by Stage and Target, H2 2015

Number of Products by Stage and Mechanism of Action, H2 2015

Number of Products by Stage and Route of Administration, H2 2015

Number of Products by Stage and Molecule Type, H2 2015

Diabetic Macular Edema Therapeutics - Recent Pipeline Updates, H2 2015

Diabetic Macular Edema - Dormant Projects, H2 2015

Diabetic Macular Edema - Dormant Projects (Contd..1), H2 2015

Diabetic Macular Edema - Dormant Projects (Contd..2), H2 2015

Diabetic Macular Edema - Discontinued Products, H2 2015

List of Figures

Number of Products under Development for Diabetic Macular Edema, H2 2015

Number of Products under Development for Diabetic Macular Edema - Comparative Analysis, H2 2015

Number of Products under Development by Companies, H2 2015

Number of Products under Investigation by Universities/Institutes, H2 2015

Comparative Analysis by Clinical Stage Development, H2 2015

Comparative Analysis by Early Stage Products, H2 2015

Assessment by Monotherapy Products, H2 2015

Number of Products by Top 10 Targets, H2 2015

Number of Products by Stage and Top 10 Targets, H2 2015

Number of Products by Top 10 Mechanism of Actions, H2 2015

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015

Number of Products by Top 10 Routes of Administration, H2 2015

Number of Products by Stage and Top 10 Routes of Administration, H2 2015

Number of Products by Top 10 Molecule Types, H2 2015

Number of Products by Stage and Top 10 Molecule Types, H2 2015

Note: Product cover images may vary from those shown
3 of 4

Aciont Inc.
ActiveSite Pharmaceuticals, Inc.
Acucela Inc.
Aerpio Therapeutics, Inc.
Allergan Plc
Ampio Pharmaceuticals, Inc.
Astellas Pharma Inc.
Avalanche Biotechnologies, Inc.
Chengdu Kanghong Pharmaceuticals Group Co., Ltd.
Chong Kun Dang Pharmaceutical Corp.
Dyax Corp.
EyeGate Pharmaceuticals, Inc.
EyeGene, Inc.
F. Hoffmann-La Roche Ltd.
Gene Signal International SA
Genmab A/S
Icon Bioscience, Inc.
Kala Pharmaceuticals, Inc.
Kowa Company, Ltd.
Mabion SA
MacuCLEAR, Inc.
NicOx S.A.
Oculis ehf
Ohr Pharmaceutical Inc.
Pfizer Inc.
Quark Pharmaceuticals, Inc.
R-Tech Ueno, Ltd.
Regeneron Pharmaceuticals, Inc.
Santen Pharmaceutical Co., Ltd.
SciFluor Life Sciences, LLC
Senju Pharmaceutical Co., Ltd.
ThromboGenics NV
Verseon Corporation

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PLEASE SELECT A FORMAT

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.

HAVE A QUESTION?

If you have a more general question about our products please try our

FAQ SECTION

RELATED PRODUCTS from Db

Our Clients

  • AB Sciex
  • Eli Lilly and Company
  • B. Braun Melsungen AG
  • Astellas Pharma, Inc.
  • Hologic Inc.
  • Merck & Co., Inc.